Browsing by Author "Karla Solo"

Filter results by typing the first few letters
Now showing 1 - 2 of 2
  • No Thumbnail Available
    PublicationMetadata only
    American Society of Hematology 2021 guidelines on the use of anticoagulation for thromboprophylaxis in patients with COVID-19
    (2021-02-09) Adam Cuker; Eric K. Tseng; Robby Nieuwlaat; Pantep Angchaisuksiri; Clifton Blair; Kathryn Dane; Jennifer Davila; Maria T. DeSancho; David Diuguid; Daniel O. Griffin; Susan R. Kahn; Frederikus A. Klok; Alfred Ian Lee; Ignacio Neumann; Ashok Pai; Menaka Pai; Marc Righini; Kristen M. Sanfilippo; Deborah Siegal; Mike Skara; Kamshad Touri; Elie A. Akl; Imad Bou Akl; Mary Boulos; Romina Brignardello-Petersen; Rana Charide; Matthew Chan; Karin Dearness; Andrea J. Darzi; Philipp Kolb; Luis E. Colunga-Lozano; Razan Mansour; Gian Paolo Morgano; Rami Z. Morsi; Atefeh Noori; Thomas Piggott; Yuan Qiu; Yetiani Roldan; Finn Schünemann; Adrienne Stevens; Karla Solo; Matthew Ventresca; Wojtek Wiercioch; Reem A. Mustafa; Holger J. Schünemann; Ramathibodi Hospital; Michael G. DeGroote School of Medicine; School of Medicine; Albert Ludwigs Universität Freiburg, Medizinische Fakultät; L'Hôpital d'Ottawa; American University of Beirut; King Hussein Cancer Center; McMaster University; Pontificia Universidad Católica de Chile; The University of Chicago; McMaster University, Faculty of Health Sciences; Universitätsklinikum Freiburg; Penn Medicine; Washington University School of Medicine in St. Louis; New York Presbyterian Hospital; Yale School of Medicine; Kaiser Permanente; Saint Michael's Hospital University of Toronto; Leids Universitair Medisch Centrum; Vagelos College of Physicians and Surgeons; St. Joseph's Healthcare Hamilton; Hôpitaux Universitaires de Genève; Universidad de Guadalajara; University of Kansas Medical Center; Albert Einstein College of Medicine of Yeshiva University; Ottawa Hospital Research Institute; The Johns Hopkins Hospital; Research and Development; Prohealth NY
    Background: Coronavirus disease 2019 (COVID-19)-related critical illness and acute illness are associated with a risk of venous thromboembolism (VTE). Objective: These evidence-based guidelines of the American Society of Hematology (ASH) are intended to support patients, clinicians, and other health care professionals in decisions about the use of anticoagulation for thromboprophylaxis for patients with COVID-19-related critical illness and acute illness who do not have confirmed or suspected VTE. Methods: ASH formed a multidisciplinary guideline panel and applied strict management strategies to minimize potential bias from conflicts of interest. The panel included 3 patient representatives. The McMaster University GRADE Centre supported the guideline-development process, including performing systematic evidence reviews (up to 19 August 2020). The panel prioritized clinical questions and outcomes according to their importance for clinicians and patients. The panel used the Grading of Recommendations Assessment, Development and Evaluation (GRADE) approach, including GRADE Evidence-to-Decision frameworks, to assess evidence and make recommendations, which were subject to public comment. Results: The panel agreed on 2 recommendations. The panel issued conditional recommendations in favor of prophylactic-intensity anticoagulation over intermediate-intensity or therapeutic-intensity anticoagulation for patients with COVID-19-related critical illness or acute illness who do not have confirmed or suspected VTE. Conclusions: These recommendations were based on very low certainty in the evidence, underscoring the need for high-quality, randomized controlled trials comparing different intensities of anticoagulation. They will be updated using a living recommendation approach as new evidence becomes available.
  • No Thumbnail Available
    PublicationMetadata only
    American Society of Hematology living guidelines on the use of anticoagulation for thromboprophylaxis in patients with COVID-19: May 2021 update on the use of intermediate-intensity anticoagulation in critically ill patients
    (2021-10-26) Adam Cuker; Eric K. Tseng; Robby Nieuwlaat; Pantep Angchaisuksiri; Clifton Blair; Kathryn Dane; Jennifer Davila; Maria T. DeSancho; David Diuguid; Daniel O. Griffin; Susan R. Kahn; Frederikus A. Klok; Alfred Ian Lee; Ignacio Neumann; Ashok Pai; Marc Righini; Kristen M. Sanfilippo; Deborah Siegal; Mike Skara; Deirdra R. Terrell; Kamshad Touri; Elie A. Akl; Imad Bou Akl; Antonio Bognanni; Mary Boulos; Romina Brignardello-Petersen; Rana Charide; Matthew Chan; Karin Dearness; Andrea J. Darzi; Philipp Kolb; Luis E. Colunga-Lozano; Razan Mansour; Gian Paolo Morgano; Rami Z. Morsi; Giovanna Muti-Schunemann; Atefeh Noori; Binu A. Philip; Thomas Piggott; Yuan Qiu; Yetiani Roldan; Finn Schunemann; Adrienne Stevens; Karla Solo; Wojtek Wiercioch; Reem A. Mustafa; Holger J. Schunemann; Ramathibodi Hospital; Michael G. DeGroote School of Medicine; School of Medicine; Albert Ludwigs Universität Freiburg, Medizinische Fakultät; American University of Beirut; King Hussein Cancer Center; McMaster University; University of Oklahoma Health Sciences Center; Pontificia Universidad Católica de Chile; The University of Chicago; Universitätsklinikum Freiburg; Penn Medicine; Washington University School of Medicine in St. Louis; New York Presbyterian Hospital; Yale School of Medicine; Kaiser Permanente; Saint Michael's Hospital University of Toronto; Leids Universitair Medisch Centrum; Vagelos College of Physicians and Surgeons; St. Joseph's Healthcare Hamilton; Hôpitaux Universitaires de Genève; Universidad de Guadalajara; University of Kansas Medical Center; Albert Einstein College of Medicine of Yeshiva University; Ottawa Hospital Research Institute; The Johns Hopkins Hospital; Research and Development at United Health Group Minnetonka; NJ; Prohealth NY
    Background: COVID-19-related critical illness is associated with an increased risk of venous thromboembolism (VTE). Objective: These evidence-based guidelines of the American Society of Hematology (ASH) are intended to support patients, clinicians, and other health care professionals in making decisions about the use of anticoagulation for thromboprophylaxis in patients with COVID-19-related critical illness who do not have confirmed or suspected VTE. Methods: ASH formed a multidisciplinary guideline panel that included 3 patient representatives and applied strategies to minimize potential bias from conflicts of interest. The McMaster University Grading of Recommendations Assessment, Development and Evaluation (GRADE) Centre supported the guideline development process by performing systematic evidence reviews (up to 5 March 2021). The panel prioritized clinical questions and outcomes according to their importance for clinicians and patients. The panel used the GRADE approach to assess evidence and make recommendations, which were subject to public comment. This is an update on guidelines published in February 2021. Results: The panel agreed on 1 additional recommendation. The panel issued a conditional recommendation in favor of prophylactic-intensity over intermediate-intensity anticoagulation in patients with COVID-19-related critical illness who do not have confirmed or suspected VTE. Conclusions: This recommendation was based on low certainty in the evidence, which underscores the need for additional high-quality, randomized, controlled trials comparing different intensities of anticoagulation in critically ill patients. Other key research priorities include better evidence regarding predictors of thrombosis and bleeding risk in critically ill patients with COVID-19 and the impact of nonanticoagulant therapies (eg, antiviral agents, corticosteroids) on thrombotic risk.